Rachel M. Smith

Rachel M. Smith

Auto-generated profile, based on publicly available information

Rachel M. Smith

Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRachel M. Smith
Rachel M. Smith
TNTuan Anh Nguyen
Tuan Anh Nguyen
HHHoang Thi Thanh Ha
Hoang Thi Thanh Ha
PTPham Hong Thang
Pham Hong Thang
CTCao Thuy
Cao Thuy
JHJulie R. Harris
Julie R. Harris
Background An estimated 120,000 HIV-associated cryptococcal meningitis (CM) cases occur each year in South and Southeast Asia; early treatment may improve outcomes. The World Health Organization (WHO) recently recommended screening HIV-infected adults with CD4<100 cells/mm 3 for serum cryptococcal antigen (CrAg), a marker of early cryptococcal infection, in areas of high CrAg prevalence. We evaluated CrAg prevalence and cost-effectiveness of this screening strategy in HIV-infected adults in northern and southern Vietnam. Methods Serum samples were collected and stored during 2009–2012 in Hanoi and Ho Chi Minh City, Vietnam, from HIV-infected, ART-naïve patients presenting to care in 12 clinics. All specimens from patients with CD4<100 cells/mm 3 were tested using the CrAg lateral flow assay. We obtained cost estimates from laboratory staff, clinicians and hospital administrators in Vietnam, and evaluated cost-effectiveness using WHO guidelines. Results Sera from 226 patients [104 (46%) from North Vietnam and 122 (54%) from the South] with CD4<100 cells/mm 3 were available for CrAg testing. Median CD4 count was 40 (range 0–99) cells/mm 3 . Nine (4%; 95% CI 2–7%) specimens were CrAg-positive. CrAg prevalence was higher in South Vietnam (6%; 95% CI 3–11%) than in North Vietnam (2%; 95% CI 0–6%) (p = 0.18). Cost per life-year gained under a screening scenario was $190, $137, and $119 at CrAg prevalences of 2%, 4% and 6%, respectively. Conclusion CrAg prevalence was higher in southern compared with northern Vietnam; however, CrAg screening would be considered cost-effective by WHO criteria in both regions. Public health officials in Vietnam should consider adding cryptococcal screening to existing national guidelines for HIV/AIDS care.

19 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRachel M. Smith
Rachel M. Smith
AMAdamma Mba-Jonas
Adamma Mba-Jonas
MTMathieu Tourdjman
Mathieu Tourdjman
TSTrisha Schimek
Trisha Schimek
EDEmilio DeBess
Emilio DeBess
JHJulie R. Harris
Julie R. Harris
Cryptococcus gattii is a fungal pathogen causing an emerging outbreak in the United States Pacific Northwest (PNW). Treatment guidelines for cryptococcosis are primarily based on data from C. neoformans infections; applicability to PNW C. gattii infection is unknown. We evaluated the relationship between initial antifungal treatment and outcomes for PNW C.gattii patients. Cases were defined as culture-confirmed invasive C. gattii infections among residents of Oregon and Washington States during 2004–2011. Clinical data were abstracted from medical records through one year of follow-up. Recommended initial treatment for central nervous system (CNS), bloodstream, and severe pulmonary infections is amphotericin B and 5-flucytosine; for non-severe pulmonary infections, recommended initial treatment is fluconazole. Alternative initial treatment was defined as any other initial antifungal treatment. Seventy patients survived to diagnosis; 50 (71%) received the recommended initial treatment and 20 (29%) received an alternative. Fewer patients with pulmonary infections [21 (64%)] than CNS infections [25 (83%)] received the recommended initial treatment (p = 0.07). Among patients with pulmonary infections, those with severe infections received the recommended initial treatment less often than those with non-severe infections (11% vs. 83%, p<0.0001). Eight patients with severe pulmonary infections received alternative initial treatments; three died. Four patients with non-severe pulmonary infections received alternative initial treatments; two died. There was a trend towards increased three-month mortality among patients receiving alternative vs. recommended initial treatment (30% vs. 14%, p = 0.12), driven primarily by increased mortality among patients with pulmonary disease receiving alternative vs. recommended initial treatment (42% vs. 10%, p = 0.07). C.gattii patients with pulmonary infections – especially severe infections – may be less likely to receive recommended treatment than those with CNS infections; alternative treatment may be associated with increased mortality. Reasons for receipt of alternative treatment among C.gattii patients in this area should be investigated, and clinician awareness of recommended treatment reinforced.

27 June 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RSRachel M. Smith
Rachel M. Smith
MTMargaret Tipple
Margaret Tipple
MCMuddasar N. Chaudry
Muddasar N. Chaudry
MSMelissa K. Schaefer
Melissa K. Schaefer
BPBenjamin J. Park
Benjamin J. Park
Since September 2012, the Centers for Disease Control and Prevention (CDC) and state and local health departments have been investigating an outbreak of fungal infections associated with injections from three lots of contaminated methylprednisolone acetate produced at a single compounding pharmacy.1 As of May 6, 2013, a total of 741 cases have been reported in 20 states, with 55 deaths. The primary pathogen isolated from patient specimens has been Exserohilum rostratum, which has also been recovered from sealed vials of methylprednisolone acetate. Before this outbreak, human infections with E. rostratum were rarely reported.2,3

17 October 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RSRachel M Smith
Rachel M Smith
ELEbbing Lautenbach
Ebbing Lautenbach
SOSylvia Omulo
Sylvia Omulo
RARafael Araos
Rafael Araos
DCDouglas R Call
Douglas R Call
BPBenjamin J Park
Benjamin J Park
Rachel M Smith, Ebbing Lautenbach, Sylvia Omulo, Rafael Araos, Douglas R Call, C P Girish Kumar, Fahmida Chowdhury, L Clifford McDonald, Benjamin J Park; Human

16 July 2021 in BMC Public Health
Verified
Journal Article
Open access
PDF file
ASAditya Sharma
Aditya Sharma
ULUlzii-Orishikh Luvsansharav
Ulzii-Orishikh Luvsansharav
PPPrabasaj Paul
Prabasaj Paul
JLJoseph D. Lutgring
Joseph D. Lutgring
DCDouglas R. Call
Douglas R. Call
RSRachel M. Smith
Rachel M. Smith
Background: Antimicrobial resistance is a global health emergency. Persons colonized with multidrug-resistant organisms (MDROs) are at risk for developing subsequent multidrug-resistant infections, as colonization represents an important precursor to invasive infection. Despite reports documenting the worldwide dissemination of MDROs, fundamental questions remain regarding the burden of resistance, metrics to measure prevalence, and determinants of spread. We describe a multi-site colonization survey protocol that aims to quantify the population-based prevalence and associated risk factors for colonization with high-threat MDROs among community dwelling participants and patients admitted to hospitals within a defined population-catchment area. Methods: Researchers in five countries (Bangladesh, Chile, Guatemala, Kenya, and India) will conduct a cross-sectional, population-based prevalence survey consisting of a risk factor questionnaire and collection of specimens to evaluate colonization with three high-threat MDROs: extended-spectrum cephalosporin-resistant Enterobacteriaceae (ESCrE), carbapenem-resistant Enterobacteriaceae (CRE), and methicillin-resistant Staphylococcus aureus (MRSA). Healthy adults residing in a household within the sampling area will be enrolled in addition to eligible hospitalized adults. Colonizing isolates of these MDROs will be compared by multilocus sequence typing (MLST) to routinely collected invasive clinical isolates, where available, to determine potential pathogenicity. A colonizing MDRO isolate will be categorized as potentially pathogenic if the MLST pattern of the colonizing isolate matches the MLST pattern of an invasive clinical isolate. The outcomes of this study will be estimates of the population-based prevalence of colonization with ESCrE, CRE, and MRSA; determination of the proportion of colonizing ESCrE, CRE, and MRSA with pathogenic characteristics based on MLST; identification of factors independently associated with ESCrE, CRE, and MRSA colonization; and creation an archive of ESCrE, CRE, and MRSA isolates for future study. Discussion: This is the first study to use a common protocol to evaluate population-based prevalence and risk factors associated with MDRO colonization among community-dwelling and hospitalized adults in multiple countries with diverse epidemiological conditions, including low- and middle-income settings. The results will be used to better describe the global epidemiology of MDROs and guide the development of mitigation strategies in both community and healthcare settings. These standardized baseline surveys can also inform future studies seeking to further characterize MDRO epidemiology globally.

5 July 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ELEbbing Lautenbach
Ebbing Lautenbach
MMMosepele Mosepele
Mosepele Mosepele
RSRachel M Smith
Rachel M Smith
ASAshley Styczynski
Ashley Styczynski
RGRobert Gross
Robert Gross
NMNaledi Mannathoko
Naledi Mannathoko
Background: The epidemiology of extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) in low- and middle-income countries (LMICs) is poorly described. Identifying risk factors for ESCrE colonization is critical to inform antibiotic resistance reduction strategies because colonization is typically a precursor to infection. Methods: From 15 January 2020 to 4 September 2020, we surveyed a random sample of clinic patients at 6 sites in Botswana. We also invited each enrolled participant to refer up to 3 adults and children. All participants had rectal swabs collected that were inoculated onto chromogenic media followed by confirmatory testing. Data were collected on demographics, comorbidities, antibiotic use, healthcare exposures, travel, and farm and animal contact. Participants with ESCrE colonization (cases) were compared with noncolonized participants (controls) to identify risk factors for ESCrE colonization using bivariable, stratified, and multivariable analyses. Results: A total of 2000 participants were enrolled. There were 959 (48.0%) clinic participants, 477 (23.9%) adult community participants, and 564 (28.2%) child community participants. The median (interquartile range) age was 30 (12–41) and 1463 (73%) were women. There were 555 cases and 1445 controls (ie, 27.8% of participants were ESCrE colonized). Independent risk factors (adjusted odds ratio [95% confidence interval]) for ESCrE included healthcare exposure (1.37 [1.08–1.73]), foreign travel [1.98 (1.04–3.77]), tending livestock (1.34 [1.03–1.73]), and presence of an ESCrE-colonized household member (1.57 [1.08–2.27]). Conclusions: Our results suggest healthcare exposure may be important in driving ESCrE. The strong links to livestock exposure and household member ESCrE colonization highlight the potential role of common exposure or household transmission. These findings are critical to inform strategies to curb further emergence of ESCrE in LMICs.